Financial reports.

Responsible stewardship.

As a 501(c)3 not-for-profit, public interest corporation, Alliance for Cancer Gene Therapy carefully manages its resources to ensure organizational stability, operational excellence and sound investments. Its fiscal year begins May 1 and ends April 30. 

100% of all public donations directly support programs related to frontline scientists working on thoroughly vetted and responsibly monitored cancer cell and gene therapy research. All management, general and fundraising expenses are underwritten by a separate fund. 

Alliance for Cancer Gene Therapy is a Gold Seal accredited non-profit as confirmed by GuideStar. It is recognized by the Better Business Bureau as a trustworthy organization.